来曲唑-HCG与FSH-HCG启动卵母细胞体外成熟在卵母细胞成熟异常女性中的比较:一项回顾性研究
本研究为2009年1月至2023年4月在私立生殖诊所开展的回顾性研究,比较来曲唑-HCG与FSH-HCG启动的IVM在卵母细胞成熟异常(至少两次取卵均获未成熟卵母细胞的IVF失败)女性中的差异。FSH-HCG组75例,来曲唑-HCG组52例。来曲唑-HCG组每患者中位MII卵母细胞率、受精率及妊娠数更高,但获卵数更少。来曲唑-HCG启动可能获得成熟卵母细胞、临床妊娠和活产,但需进一步研究。
要点
- FSH-HCG组获卵数中位数显著高于来曲唑-HCG组(9 vs 5,P<0.001)。
- 来曲唑-HCG组每患者中位MII卵母细胞率显著高于FSH-HCG组(33.3% vs 0.0%,P<0.001)。
- 来曲唑-HCG组中位受精率高于FSH-HCG组(66.7% vs 50.0%,P=0.027),全部妊娠均见于来曲唑-HCG组(5 vs 0,P=0.042)。
核心结论
- 对于因卵母细胞成熟异常导致既往IVF失败的患者,用来曲唑-HCG启动IVM可能获得成熟卵母细胞、临床妊娠和活产。
- 来曲唑启动对不同卵母细胞成熟异常亚型的有效性需进一步研究,需纳入更大样本量的研究。
研究设计与样本
- 回顾性研究,于2009年1月至2023年4月在私立生殖诊所开展。
- 最终分析纳入75例FSH-HCG启动IVM组(第1组)和52例来曲唑-HCG启动IVM组(第2组)女性。
- 卵母细胞成熟异常定义为至少两个IVF周期取卵均获未成熟卵母细胞而失败。
主要发现
- 第1组获卵数中位数显著高于第2组{9[四分位距(IQR)1-5] vs 5(IQR 1-18);P<0.001}。
- 取卵时卵母细胞成熟阶段两组间无差异(P>0.05)。
- IVM结束时,第1组成熟卵母细胞为73/666,第2组为106/322;第2组每患者中位MII卵母细胞率更高[33.3%(IQR 66.7-100.0%)vs 0.0%(IQR 0.0-22.2%);P<0.001]。
- 第2组中位受精率更高[66.7%(IQR 50.0-100.0%)vs 50.0%(IQR 0.0-66.7%);P=0.027]。
- 第2组2级胚胎比例更高(58.5% vs 6.3%),第1组3级胚胎比例更高(93.8% vs 24.4%;P<0.001);全部妊娠均见于第2组(5 vs 0;P=0.042)。
临床怎么用
- 作者认为,对于因卵母细胞成熟异常导致既往IVF失败的患者,用来曲唑-HCG启动IVM可能获得成熟卵母细胞、临床妊娠和活产。
- 作者指出,来曲唑启动对不同卵母细胞成熟异常亚型的有效性需进一步研究,需纳入更大样本量的研究。
局限性
- 原文报告为回顾性研究。
- 来曲唑启动对卵母细胞成熟异常各亚型的有效性需进一步研究,需纳入更大样本量的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Are there differences between in-vitro maturation (IVM) primed with letrozole-human chorionic gonadotrophin (HCG) and IVM primed with FSH-HCG in women with oocyte maturation abnormalities (OMAs), defined as at least two failed IVF cycles where immature oocytes were retrieved? DESIGN: This retrospective study was conducted at a private fertility clinic from January 2009 to April 2023. The final analysis included 75 women in Group 1 (IVM primed with FSH-HCG) and 52 women in Group 2 (IVM primed with letrozole-HCG). RESULTS: A significantly higher median number of oocytes was obtained in Group 1 compared with Group 2 {9 [interquartile range (IQR) 1-5] versus 5 (IQR 1-18); P < 0.001}. However, no differences in oocyte maturation stage at collection were found between the groups (P > 0.05). At the end of IVM, Group 1 had 73/666 mature oocytes and Group 2 had 106/322 mature oocytes, and the median metaphase II oocyte rate per patient was higher in Group 2 [33.3% (IQR 66.7-100.0%) versus 0.0% (IQR 0.0-22.2%); P < 0.001]. Moreover, Group 2 demonstrated a higher median fertilization rate [66.7% (IQR 50.0-100.0%) versus 50.0% (IQR 0.0-66.7%); P = 0.027]. Group 2 had a higher proportion of Grade 2 embryos (58.5% versus 6.3%), and Group 1 had a higher proportion of Grade 3 embryos (93.8% vs 24.4%; P < 0.001). Notably, all pregnancies obtained in the study were in Group 2 (5 versus 0; P = 0.042). CONCLUSIONS: IVM primed with letrozole-HCG in women with prior failed IVF cycles due to OMAs may result in mature oocytes, clinical pregnancies and live births. The effectiveness of letrozole priming for the subtypes of OMAs needs further investigation, with studies including greater numbers of cases.
引用
- Hatirnaz S, Hatirnaz E, Urkmez SS, et al. Oocyte in-vitro maturation primed with letrozole-HCG versus FSH-HCG in women with oocyte maturation abnormalities: a retrospective study. Reprod Biomed Online. 2023. PMID: 38194886. doi:10.1016/j.rbmo.2023.103620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。